Home
Knee1 Headlines

FDA Says Remicade Users Suffer Ailments

Printer Friendly Version     Email this Article     Links/Reprints

FDA Says Remicade Users Suffer Ailments

FDA Says Remicade Users Suffer Ailments

August 24, 2004

The Food and Drug Administration and manufacturer Centocor are warning doctors that patients receiving the drug Remicade to treat rheumatoid arthritis and Crohn's disease have suffered sometimes fatal blood and central nervous system disorders. Centocor's Aug. 11 warning letter to doctors said the "causal relationship" between the ailments and Remicade therapy "remains unclear."

The Malvern, Pa.-based company, working with the federal drug regulatory agency, revised its label for the monoclonal antibody.

Patients receiving the drug suffered reductions in their red and white blood cell, granulocyte and platelet counts, leaving them more vulnerable to abnormal bleeding and infections. In some instances, patients died. In rare instances, patients suffered central nervous system disorders, including confusing immune system responses that swelled, then decayed, blood vessels.

Remicade was approved for use in the United States on Aug. 24, 1998. Worldwide, 509,000 patients have taken it. In late July, a European advisory committee approved expanding its use for treating people with psoriatic arthritis.


Previous Stories

Osteoarthritis Risk May be in Your Genes

Study: Tests May Make Donated Tissue Safer

Common Sports Injuries of the Amateur Athlete

more Feature Stories


RSS

KNEE REPLACEMENT SURGERY COST IN INDIA
By lyfboat
more more Blogs RSS

DR Dunn and IAGH
By tblair

Posted: May 23, 2017
 I understand DR Dunn has retired from medicine..Does anyone know of any other doctor who is doing IAGH injections ?

more more Forums Create a Topic

Female Sport Injury
Female Sports Injuries
Learn about the increase in sports injuries among women, the causes, treatment ...
more more Featured Videos

 
Dr. Robert Klapper

Dr. Robert Klapper:

Preventing Knee Surgery
  more
  more Heroes
  nominate a Hero
  Hero policy